CST is having a picnic recently, but I notice the company hasn't put out much information over this 'boom' time. I mean there's no announcement of anything other than 'steady as she goes'. It seems to be punters who are putting their backsides on the line. question is - is it worth doing so?
Things I like about CST are its low share registry number, its position in its market, its product (for a bio, it actually has something to sell that works), and the need to replace an outmoded form of TB testing acknowledged by many authorities. All very positive there.
Things that concern me. The uncertainty over the US and Japanese approvals. The US in particular has a great track record of screwing foreign companies that look like making good in the US, and Japan is a total basket case in any regulatory sense - they can never make their minds up. CST has a test and not a cure, so while the threat remains for TB to get more virulent then CST obviously has advantages, though if someone around the corner has a cure?....
Anyway, I've taken a punt, though I haven't overdone it. CST has been around a fair while and I don't think it should suffer too much of a drop if there is any cooling off due to non-approval at this time. I think it will win out eventually. But I still think there's a need for caution. I did real well out of CST a few years ago, though didn't get out at the peak, still, I wonder where the peak will be this time around?
CST Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
